- Home
- GLTO vs HBIO Comparison
GLTO vs HBIO Comparison
Compare GLTO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- HBIO
- Stock Information
- Founded
- GLTO 2011
- HBIO 1901
- Country
- GLTO Denmark
- HBIO United States
- Employees
- GLTO N/A
- HBIO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- GLTO Health Care
- HBIO Industrials
- Exchange
- GLTO Nasdaq
- HBIO Nasdaq
- Market Cap
- GLTO 23.7M
- HBIO 24.6M
- IPO Year
- GLTO 2020
- HBIO 2000
- Fundamental
- Price
- GLTO $10.99
- HBIO $0.40
- Analyst Decision
- GLTO Buy
- HBIO Buy
- Analyst Count
- GLTO 1
- HBIO 3
- Target Price
- GLTO $10.00
- HBIO $2.50
- AVG Volume (30 Days)
- GLTO 7.6M
- HBIO 498.1K
- Earning Date
- GLTO 10-31-2025
- HBIO 11-06-2025
- Dividend Yield
- GLTO N/A
- HBIO N/A
- EPS Growth
- GLTO N/A
- HBIO N/A
- EPS
- GLTO N/A
- HBIO N/A
- Revenue
- GLTO N/A
- HBIO $88,750,000.00
- Revenue This Year
- GLTO N/A
- HBIO N/A
- Revenue Next Year
- GLTO N/A
- HBIO $7.02
- P/E Ratio
- GLTO N/A
- HBIO N/A
- Revenue Growth
- GLTO N/A
- HBIO N/A
- 52 Week Low
- GLTO $2.01
- HBIO $0.28
- 52 Week High
- GLTO $31.70
- HBIO $2.82
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- HBIO 34.47
- Support Level
- GLTO $10.53
- HBIO $0.41
- Resistance Level
- GLTO $18.45
- HBIO $0.44
- Average True Range (ATR)
- GLTO 2.35
- HBIO 0.02
- MACD
- GLTO 0.43
- HBIO -0.00
- Stochastic Oscillator
- GLTO 26.56
- HBIO 1.97
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.